Rixubis Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The rixubis market research report is one of a series of new reports that provides rixubis market statistics, including rixubis industry global market size, regional shares, competitors with rixubis market share, detailed rixubis market segments, market trends and opportunities, and any further data you may need to thrive in the rixubis industry. This rixubis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to growing demand for recombinant therapies, increasing focus on personalized medicine, government initiatives to improve rare disease management, improved affordability of advanced treatments, and enhanced diagnostic accuracy for genetic disorders. Major trends in the forecast period include increasing adoption of long-acting recombinant products, growing preference for home-based treatment solutions, advancements in delivery mechanisms, development of cost-effective biosimilars, and integration of digital health tools for patient monitoring.

The growing prevalence of hemophilia is expected to significantly drive the expansion of the rixubis market in the future. Hemophilia is a genetic bleeding disorder that impairs the blood’s ability to clot, leading to prolonged bleeding episodes. The rise in hemophilia cases can be attributed to advances in diagnostic techniques, heightened awareness, and population growth, which has led to the identification of more cases globally. Rixubis addresses this issue by providing recombinant factor IX therapy, which helps prevent and control bleeding episodes, enabling individuals with hemophilia B to maintain better health and reduce the risks associated with clotting deficiencies. For example, according to a report by the United Kingdom Hemophilia Centre Doctors’ Organization (UKHCDO) in November 2022, new registrations of Hemophilia A increased from 16 in 2021 to 19 in 2022. The rising number of hemophilia cases is thus driving the growth of the rixubis market.

The increasing prevalence of bleeding diseases is also expected to contribute to the growth of the rixubis market. These diseases, which impair the blood’s ability to clot properly and lead to excessive bleeding, are becoming more common due to better diagnosis, genetic factors, and growing awareness. Rixubis helps manage these conditions by delivering recombinant factor IX therapy, which supports effective blood clot formation, reduces bleeding frequency, and improves the quality of life for those with clotting disorders such as hemophilia B. For instance, in a report published by the UKHCDO in December 2022, it was noted that 4,123 males and 11,288 females with von Willebrand disease were registered and treated in 2021/22, including 371 new cases in 2022. This increase in bleeding disease diagnoses is driving demand for treatments such as rixubis.

The rising allocation of research and development (R&D) funding in healthcare is another factor expected to drive the growth of the rixubis market. R&D funding refers to financial resources dedicated to advancing medical research and developing new healthcare treatments and technologies. The increase in R&D funding is driven by factors such as growing healthcare needs, technological advancements, and government support for medical research. This funding helps facilitate the development of treatments such as rixubis by supporting clinical trials and improving therapeutic options for patients. For example, according to the Congressional Research Service, R&D funding in the U.S. is projected to reach $209.7 billion in fiscal year 2024, marking an increase of $8.9 billion from the previous year. The growing investment in healthcare R&D is expected to fuel the expansion of the rixubis market.

The key company operating in the rixubis market is Takeda Pharmaceutical Company

North America was the largest region in the rixubis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rixubis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rixubis market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Rixubis is a recombinant factor IX therapy designed to treat and prevent bleeding episodes in individuals with hemophilia B. It works by replacing the missing or deficient factor IX, helping to achieve better bleeding control and improve the patient's quality of life.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of Rixubis include recombinant factor IX and plasma-derived factor IX. Recombinant factor IX is a genetically engineered protein that treats hemophilia B by replacing the deficient or missing clotting factor IX in the blood. It is used for indications such as routine prophylaxis, treatment of bleeding episodes, and peri-operative management, supporting both hemophilia B treatment and surgical procedures. The patients who use this therapy include pediatric, adult, and geriatric populations.

The rixubis market consists of sales of products such as lyophilized powder and single-use vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.